Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

The Dawn of a New Era in Kidney Cancer Treatment

The Dawn of a New Era in Kidney Cancer Treatment

Decades of oncology research finally appear to have taken a major step in the right direction: a safe, effective option for kidney cancer patients at high risk of recurrence after surgery— adjuvant (preventive) treatment. Yes, once again, the answer is immunotherapy!

Pembrolizumab (Keytruda) monotherapy after nephrectomy (kidney cancer surgery), compared with placebo, was associated with significantly longer disease-free survival (77.3% versus 68.1%, respectively), according to results of the randomized phase 3 KEYNOTE-564 study, which have raised high hopes. Median patient follow-up was 24 months.

The results come from the first interim analysis in patients at high recurrence risk with clear-cell renal cell carcinoma, including data from 994 patients.

The study's lead author, Dr. Toni Choueiri of the Dana Farber Cancer Institute in Boston, reported for the pembrolizumab group a survival rate of 96.6% at month 24, compared with 93.5% for the placebo group (hazard ratio [HR] for death, 0.54).

However, grade 3 or higher adverse effects of any cause occurred at nearly twice the rate with pembrolizumab as with placebo (32.4% versus 17.7%). The new study appeared in the New England Journal of Medicine on August 18 in an online publication.

The study results were first presented at this year's virtual American Society of Clinical Oncology (ASCO) meeting.

Adjuvant Treatment in Kidney Cancer

Until now, the only FDA-approved drug for postoperative adjuvant treatment of kidney cancer has been sunitinib, which received approval in 2017 (see the relevant approval). However, sunutinib has not achieved the desired use in clinical practice, probably because of its many adverse effects, lack of improved quality of life and unsatisfactory survival outcomes. Despite FDA approval in the United States, sunitinib has not been approved for adjuvant use by the European Medicines Agency (EMA) and has limited clinical use given its low benefit-to-risk ratio.

Numerous studies have investigated potential adjuvant treatments for kidney cancer since the 1980s

The standard treatment for patients diagnosed with early-stage and/or locally advanced kidney cancer is partial or complete nephrectomy; however, approximately half of patients experience cancer recurrence after surgery. With this study, for the first time, we have an effective adjuvant immunotherapy option for patients with renal cell carcinoma whose tumor has been removed surgically and who have a high risk of recurrence.

The researchers will continue to follow overall survival outcomes, a secondary endpoint of the study. A 46% reduction in the risk of death with immunotherapy is encouraging (hazard ratio [HR] for death, 0.54).

Study Details

KEYNOTE-564 included 996 patients with clear-cell kidney cancer at high risk of recurrence after nephrectomy, with or without metastasectomy. Patients were randomly assigned in a 1:1 ratio to receive adjuvant pembrolizumab 200 mg intravenously every 3 weeks for up to 17 cycles over approximately 1 year, or placebo.

The vast majority of enrolled patients had regional disease without evidence of metastasis (M0) and an intermediate-to-high risk of recurrence after partial or complete nephrectomy. However, 5.8% of patients in both the pembrolizumab and placebo groups had M1 NED status (metastatic stage 1, no evidence of disease) after nephrectomy and resection of metastatic lesions. These patients were also at intermediate-high or high risk of recurrence.

The benefit of pembrolizumab over placebo appears to be maintained in this subgroup. PD-L1 status, geography, sex, performance status and M0/M1 are among the various subgroups examined, in which pembrolizumab appears advantageous over placebo.

In the Future...

Circulating tumor DNA is among the tissue- and blood-based biomarkers under investigation in studies that will be key to identifying patients at the highest risk of recurrence or for adjuvant treatment. Adoption of adjuvant immunotherapy raises new questions about patient selection, its use in patients with non-clear-cell renal cell carcinoma and systemic treatment after recurrence during or following adjuvant therapy.

Sources

1. Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. NEJM 19 August 2021

2. Dawn of a New Era' in the Treatment of Renal Cell Carcinoma - Medscape - Aug 18, 2021

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

The Dawn of a New Era in Kidney Cancer Treatment

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy